RE:RE:RE:RE:RE:RE:Why would you listen Jomen, the segmented numbers that iscfa posted are 2016 numbers not numbers going forward. People are consistently ripping Apparo as the weak link and while 2016 numbers are better for viemed then apparo they are currently both cash flow positive. Both companies are going make to it, viemed may get the higher valuation which is why they are splitting the companies but I don't believe they are splitting the companies because one will flourish and the other will fail.